GlaxoSmithKline | GSK - Sales Revenues

Stock Price
1,928.50
Daily Change
10.50 0.55%
Monthly
-6.56%
Yearly
31.82%
Q2 Forecast
1,986.06

GlaxoSmithKline reported GBP7.63B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Alcon AG USD 2.7B 110M Dec/2025
Almirall EUR 547.63M 12.83M Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
argenx SE USD 1.12B 132.91M Dec/2025
AstraZeneca USD 15.29B 213M Mar/2026
Bayer EUR 11.44B 1.78B Dec/2025
Biogen USD 2.25B 30M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Fresenius EUR 5.88B 400M Dec/2025
Fresenius Medical Care EUR 5.07B 180M Dec/2025
Galapagos EUR 900.82M 835.52M Dec/2025
Genmab DKK 1.06B 36M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
GRIFOLS EUR 1.98B 110M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.25B 70M Dec/2025
Merck USD 16.29B 110M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Orion EUR 417.7M 277.6M Mar/2026
Pfizer USD 17.58B 880M Dec/2025
Philips EUR 5.1B 797M Dec/2025
Recordati EUR 662M 37.65M Dec/2025
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Smith & Nephew USD 3.18B 353M Dec/2025
UCB EUR 4.25B 764M Dec/2025